These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16044759)

  • 1. [We must learn how to be better to evaluate drug benefits and risks].
    Dahl E
    Lakartidningen; 2005 Jun 27-Jul 10; 102(26-27):2003-4. PubMed ID: 16044759
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pfizer urged to respond to criticism and participate in the public debate].
    Bengt J
    Lakartidningen; 2005 Feb 21-27; 102(8):574-5. PubMed ID: 15786910
    [No Abstract]   [Full Text] [Related]  

  • 3. [Five turbulent years of coxibers. Where did the principle of caution go?].
    Håkansson J; Rosenberg P
    Lakartidningen; 2005 May 2-15; 102(18-19):1432-4. PubMed ID: 15929426
    [No Abstract]   [Full Text] [Related]  

  • 4. A proposal for evaluation of platelet aggregation and adhesiveness for clinical trials with cyclooxygenase inhibitors and nonsteroidal antiinflammatory drugs.
    Atik M
    J Am Coll Surg; 2005 Aug; 201(2):263-4. PubMed ID: 16038825
    [No Abstract]   [Full Text] [Related]  

  • 5. Painful lessons.
    Nat Rev Drug Discov; 2005 Oct; 4(10):800-3. PubMed ID: 16237842
    [No Abstract]   [Full Text] [Related]  

  • 6. [Insights and views about cardiovascular safety of COX2 inhibitors].
    Wallentin L
    Lakartidningen; 2005 Feb 28-Mar 6; 102(9):666, 668, 671. PubMed ID: 15804041
    [No Abstract]   [Full Text] [Related]  

  • 7. [Coxib debate on thin ice].
    Järhult B
    Lakartidningen; 2005 Mar 7-13; 102(10):788-9; discussion 789-90. PubMed ID: 15839175
    [No Abstract]   [Full Text] [Related]  

  • 8. 'Guidelines' or marketing for non-steroidal anti-inflammatory drug and proton pump inhibitor use?
    Graham DY
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1323-4; author reply 1325. PubMed ID: 15191515
    [No Abstract]   [Full Text] [Related]  

  • 9. The COX 2 selective inhibitors: what the newspapers have not told you.
    Simon LS
    Bull NYU Hosp Jt Dis; 2007; 65(3):229-41. PubMed ID: 17922675
    [No Abstract]   [Full Text] [Related]  

  • 10. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA; Schroy PC
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract]   [Full Text] [Related]  

  • 11. Coxibs: no better than other NSAIDS.
    Prescrire Int; 2004 Dec; 13(74):226. PubMed ID: 15612145
    [No Abstract]   [Full Text] [Related]  

  • 12. "To do no harm".
    Binymin KA; Phillips K
    Rheumatology (Oxford); 2007 Feb; 46(2):368-70; author reply 370. PubMed ID: 17116655
    [No Abstract]   [Full Text] [Related]  

  • 13. [Complete and independent scrutiny of coxiber is required].
    Håkansson J
    Lakartidningen; 2002 Nov; 99(48):4904. PubMed ID: 12523079
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life without COX 2 inhibitors: risks and benefits are determined by dose and potency.
    Sánchez-Delgado EJ
    BMJ; 2006 Jun; 332(7555):1451-2. PubMed ID: 16777893
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk assessment, drug approval, and liability.
    Somberg JC
    Am J Ther; 2006; 13(3):181-2. PubMed ID: 16772756
    [No Abstract]   [Full Text] [Related]  

  • 17. Coxibs and cardiovascular risk.
    Pijak MR; Huzicka I; Gazdik F
    CMAJ; 2005 Oct; 173(8):852. PubMed ID: 16217096
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of cyclooxygenase-2 inhibitors: are they fulfilling their promises?
    Yeomans ND
    Intern Med J; 2004 Apr; 34(4):145-7. PubMed ID: 15086691
    [No Abstract]   [Full Text] [Related]  

  • 19. Coxibs and cardiovascular risk.
    Allen MJ; McLean-Veysey P; Fleming I
    CMAJ; 2005 Oct; 173(8):853. PubMed ID: 16217098
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing the risks and benefits of celecoxib.
    Caldwell B; Beasley R; Weatherall M; Metcalfe S
    Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.